



# EL SALVADOR

## Number of new cases

**9 799**

## Number of deaths

**5 292**

## Number of prevalent cases (5-year)

**21 507**


### Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	3 062 694	3 487 702	6 550 396
<b>Incidence*</b>			
Number of new cancer cases	4 205	5 594	9 799
Age-standardized incidence rate	126.5	128.4	127.1
Risk of developing cancer before the age of 75 years (cum. risk %)	12.9	12.4	12.5
Top 3 leading cancers (ranked by cases)**	Prostate Stomach Colorectum	Breast Cervix uteri Colorectum	Breast Prostate Stomach
<b>Mortality*</b>			
Number of cancer deaths	2 290	3 002	5 292
Age-standardized mortality rate	65.1	64.6	64.7
Risk of dying from cancer before the age of 75 years (cum. risk %)	6.2	6.3	6.3
Top 3 leading cancers (ranked by deaths)**	Prostate Stomach Liver	Cervix uteri Breast Stomach	Stomach Liver Leukaemia
<b>Prevalence*</b>			
5-year prevalent cases	8 472	13 035	21 507



### Top 5 most frequent cancers\*\*


#### Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	1 392	33.1%
2nd	Stomach	350	8.3%
3rd	Colorectum	296	7.0%
4th	Leukaemia	263	6.3%
5th	Liver	209	5.0%
-	Others	1 695	40.3%

Number of new cases in 2022, males, all ages


#### Females



Rank	Cancer site	Number of cases	Percent
1st	Breast	1 612	28.8%
2nd	Cervix uteri	627	11.2%
3rd	Colorectum	396	7.1%
4th	Stomach	343	6.1%
5th	Leukaemia	300	5.4%
-	Others	2 316	41.4%

Number of new cases in 2022, females, all ages

#### Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Breast	1 612	16.5%
2nd	Prostate	1 392	14.2%
3rd	Stomach	693	7.1%
4th	Colorectum	692	7.1%
5th	Cervix uteri	627	6.4%
-	Others	4 783	48.8%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	1 612	1	16.5	4.2	332	8	6.3	0.81	4 495	20.9
Prostate	1 392	2	14.2	5.1	334	7	6.3	0.54	2 877	13.4
Stomach	693	3	7.1	0.83	593	1	11.2	0.70	934	4.3
Colorectum	692	4	7.1	0.90	373	4	7.0	0.47	1 671	7.8
Cervix uteri	627	5	6.4	1.5	367	5	6.9	0.89	1 703	7.9
Leukaemia	563	6	5.7	0.68	397	3	7.5	0.46	1 452	6.8
Liver	471	7	4.8	0.58	439	2	8.3	0.55	537	2.5
Lung	386	8	3.9	0.49	348	6	6.6	0.43	500	2.3
Brain CNS	291	9	3.0	0.37	240	9	4.5	0.31	911	4.2
Pancreas	220	10	2.2	0.28	204	10	3.9	0.26	202	0.94
NHL	184	11	1.9	0.24	96	12	1.8	0.13	498	2.3
Ovary	182	12	1.9	0.44	116	11	2.2	0.29	442	2.1
Thyroid	159	13	1.6	0.25	35	20	0.66	0.04	457	2.1
Kidney	151	14	1.5	0.23	64	15	1.2	0.10	389	1.8
Corpus uteri	124	15	1.3	0.33	36	19	0.68	0.09	375	1.7
Bladder	101	16	1.0	0.12	58	16	1.1	0.05	244	1.1
Lip, oral cavity	98	17	1.0	0.10	58	16	1.1	0.06	239	1.1
Oesophagus	87	18	0.89	0.10	79	13	1.5	0.10	106	0.49
Gallbladder	84	19	0.86	0.11	75	14	1.4	0.10	107	0.50
Hodgkin lymphoma	66	20	0.67	0.07	15	23	0.28	0.02	193	0.90
Multiple myeloma	58	21	0.59	0.09	46	18	0.87	0.07	141	0.66
Larynx	48	22	0.49	0.06	32	21	0.61	0.05	118	0.55
Testis	41	23	0.42	0.09	10	27	0.19	0.02	137	0.64
Melanoma	35	24	0.36	0.04	17	22	0.32	0.02	100	0.47
Salivary glands	34	25	0.35	0.04	13	25	0.25	0.01	95	0.44
Vulva	28	26	0.29	0.04	14	24	0.27	0.02	58	0.27
Penis	28	26	0.29	0.06	8	28	0.15	0.02	73	0.34
Oropharynx	22	28	0.23	0.03	12	26	0.23	0.01	42	0.20
Vagina	10	29	0.10	0.01	4	29	0.08	0.01	16	0.07
Nasopharynx	5	30	0.05	0.00	4	29	0.08	0.00	11	0.05
Hypopharynx	5	30	0.05	0.01	3	31	0.06	0.00	6	0.03
Kaposi sarcoma	3	32	0.03	0.00	0	32	0.00	0.00	8	0.04
<b>All cancers</b>	<b>9 799</b>	-	-	<b>12.5</b>	<b>5 292</b>	-	-	<b>6.3</b>	<b>21 507</b>	-
<b>All cancers excl. NMSC</b>	<b>9 600</b>	-	-	<b>12.4</b>	<b>5 239</b>	-	-	<b>6.2</b>	<b>20 967</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Mortality

**Country-specific data source:** National (WHO)  
**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)  
 \*\* NMSC included in other cancers  
 Age standardization using world population ([see link](#))

## References

**Website citation**  
 Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

